An FDA advisory panel expressed support for a blood test designed to detect early signs of multiple cancers, including some for which no screening alternative exists.Members of the Medical Devices Advisory Committee’s Molecular and Clinical Genetics Panel voted 7 to 2 with one abstention that the benefits of Galleri (Grail Inc.) outweigh the potential risks for adults age 50 years or older,

The gene is found predominantly in Southern Appalachia and may be one of the most powerful cancer-risk mutations ever found.

We Are ALX honors a new cohort of leaders selected in time for Hispanic Heritage Month.

Aggressive prostate cancer treatment is evolving. Find out how new therapies are changing outcomes and patient care.

On Aug. 26, FDA approved the RAS inhibitor, daraxonrasib, sponsored by Revolution Medicines Inc. and also known as Rasonque, for patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy. This episode is available on Spotify, Apple Podcasts, and Youtube. The approval was […]

A rare inherited mutation in the Epidermal Growth Factor Receptor (EGFR) gene is associated with a 25-fold increased risk of lung cancer, according to a study by investigators at Dana-Farber Cancer Institute and 23andMe Research Institute. The findings included de-identified, aggregated genetic data from more than 3.3 million 23andMe research-consented participants.

Dana-Farber's CEO and chief medical officer spoke with the Business Journal about planning work for the new hospital. Here's how Dana-Farber is planning for the first patients at its $2B hospital.

Edward Chouchani, PhD, principal investigator of the Chouchani Lab at Dana-Farber Cancer Institute, was one of 18 scientists named as finalists for the 2026 Blavatnik National Awards for Young Scientists, a significant prize for early-career researchers.

This year's Power 50: The Movement Makers are shaking things up and making things happen. Check out this year's list of powerhouse professionals effecting change in communities across Greater Boston.

Frontline researcher sees a newly approved medication as a "critical first step" toward transformation of care.

Dana-Farber researchers mapped microbes across 28 cancer types, revealing how bacteria, fungi, viruses, and parasites may interact with tumors.

A Dana-Farber clinical trial is testing DT2216 with paclitaxel to target chemotherapy resistance in patients with recurrent ovarian cancer.

From Discovery to Delivery: Charting Progress in Gynecologic Oncology | Podcasts | OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

The new landmark drug treats pancreatic cancer in its advanced stages and extends the survival rate of participants in the trial by a median of 13.2 months.

A first-of-a-kind pancreatic cancer drug given approval by the FDA on Wednesday was trialed at Dana-Farber in Boston. It offers a new approach to treating the deadly form of cancer.

The companies have not published the trial data but said in a news release that the experimental treatment extended the time before cancer returned in high-risk patients.

Learn how Dana-Farber-led research helped establish ctDNA testing to guide atezolizumab after surgery for muscle-invasive bladder cancer.

The U.S. Food and Drug Administration has approved iberdomide in combination with daratumumab and dexamethasone for patients with relapsed or refractory multiple myeloma, making it the first approved cereblon E3 ligase modulator (CELMoD) for this disease.

Newer technologies are helping more cancer patients have children after treatment.

Are peptides safe, and can they increase cancer risk? Learn about unapproved peptides, FDA oversight, potential side effects, and safety concerns.

Of all 11 prospective payment system-exempt cancer hospitals, Boston-based Dana-Farber Cancer Institute had the highest nurse communication score between July 1, 2024, and June 30, 2025, according to CMS data published May 13.  The Hospital Consumer Assessment of Healthcare Providers and Systems is a national, standardized survey completed by patients after inpatient hospital stays. Eleven […]

Chimeric antigen receptor T-cell (CAR T) therapy reprograms a patient’s own immune cells to find and eliminate cancer. While it has transformative for some blood cancers, many patients eventually relapse, and the […]

Meet the 2026 CRI Lloyd J Old STARs, five bold scientists pushing the boundaries of cancer immunotherapy through high-risk, high-reward research.

The U.S. Food and Drug Administration (FDA) has approved a new therapy regimen for patients with "double-positive" metastatic breast cancer based on results of the phase 3 PATINA study led by Otto Metzger, MD, Associate Medical Director of International Strategic Initiatives at Dana-Farber Cancer Institute

A new epigenetic test could diagnose acute leukemia within hours, helping doctors identify targeted treatment options more quickly.

From doctor to patient, one young physician shares how an Ewing sarcoma diagnosis reshaped her life, career, and perspective on cancer care.